Insmed Stock (NASDAQ:INSM)
Previous Close
$78.46
52W Range
$21.92 - $80.53
50D Avg
$72.07
200D Avg
$63.90
Market Cap
$13.95B
Avg Vol (3M)
$1.80M
Beta
1.12
Div Yield
-
INSM Company Profile
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
INSM Performance
Peer Comparison
| Ticker | Company |
|---|---|
| RVMD | Revolution Medicines, Inc. |
| BGNE | BeiGene, Ltd. |
| APLS | Apellis Pharmaceuticals, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| RARE | Ultragenyx Pharmaceutical Inc. |
| AGIO | Agios Pharmaceuticals, Inc. |
| RNA | Avidity Biosciences, Inc. |
| SWTX | SpringWorks Therapeutics, Inc. |
| KROS | Keros Therapeutics, Inc. |
| BPMC | Blueprint Medicines Corporation |
| AKRO | Akero Therapeutics, Inc. |
| HALO | Halozyme Therapeutics, Inc. |
| EWTX | Edgewise Therapeutics, Inc. |
| FENC | Fennec Pharmaceuticals Inc. |
| JANX | Janux Therapeutics, Inc. |
| HRMY | Harmony Biosciences Holdings, Inc. |
| ASND | Ascendis Pharma A/S |